Posted by Michael Wonder on 28 Nov 2023
Sernova receives orphan drug and rare paediatric disease designations for its haemophilia A program from FDA
27 November 2023 - Sernova today announced the US FDA has granted both orphan drug designation and rare paediatric disease designation for the company’s haemophilia A program.
Sernova’s haemophilia A program combines the Sernova Cell Pouch with a patient’s own cells and will not require the use of immunosuppression medications.
